دورية أكاديمية
أعرض في EDS

The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine.

التفاصيل البيبلوغرافية
العنوان: The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine.
المؤلفون: Sagara I; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Zongo I; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Cairns M; London School of Hygiene & Tropical Medicine, London, United Kingdom., Yerbanga RS; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Mahamar A; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Nikièma F; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Tapily A; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Sompougdou F; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Diarra M; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Zoungrana C; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Issiaka D; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Haro A; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Sanogo K; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Aziz Sienou A; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Kaya M; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Traore S; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Thera I; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Diarra K; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Dolo A; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Kuepfer I; London School of Hygiene & Tropical Medicine, London, United Kingdom., Snell P; London School of Hygiene & Tropical Medicine, London, United Kingdom., Milligan P; London School of Hygiene & Tropical Medicine, London, United Kingdom., Ockenhouse C; PATH, Seattle, Washington, USA., Ofori-Anyinam O; GSK Vaccines, Rixensart, Belgium., Tinto H; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Djimde A; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Ouedraogo JB; Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso., Dicko A; The Malaria Research and Training Center, University of Sciences, Techniques and Technologies, Bamako, Mali., Chandramohan D; London School of Hygiene & Tropical Medicine, London, United Kingdom., Greenwood B; London School of Hygiene & Tropical Medicine, London, United Kingdom.
المصدر: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Sep 10; Vol. 75 (4), pp. 613-622.
نوع المنشور: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: Jan. 2011- : Oxford : Oxford University Press
Original Publication: Chicago, IL : The University of Chicago Press, c1992-
مواضيع طبية MeSH: Malaria* , Malaria Vaccines* , Malaria, Falciparum*/epidemiology , Malaria, Falciparum*/prevention & control, Antibody Formation ; Child ; Humans ; Infant ; Plasmodium falciparum ; Seasons ; Vaccination
مستخلص: Background: A trial in African children showed that combining seasonal vaccination with the RTS,S/AS01E vaccine with seasonal malaria chemoprevention reduced the incidence of uncomplicated and severe malaria compared with either intervention given alone. Here, we report on the anti-circumsporozoite antibody response to seasonal RTS,S/AS01E vaccination in children in this trial.
Methods: Sera from a randomly selected subset of children collected before and 1 month after 3 priming doses of RTS,S/AS01E and before and 1 month after 2 seasonal booster doses were tested for anti-circumsporozoite antibodies using enzyme-linked immunosorbent assay. The association between post-vaccination antibody titer and incidence of malaria was explored.
Results: A strong anti-circumsporozoite antibody response to 3 priming doses of RTS,S/AS01E was seen (geometric mean titer, 368.9 enzyme-linked immunosorbent assay units/mL), but titers fell prior to the first booster dose. A strong antibody response to an annual, pre-malaria transmission season booster dose was observed, but this was lower than after the primary vaccination series and lower after the second than after the first booster dose (ratio of geometric mean rise, 0.66; 95% confidence interval [CI], .57-.77). Children whose antibody response was in the upper tercile post-vaccination had a lower incidence of malaria during the following year than children in the lowest tercile (hazard ratio, 0.43; 95% CI, .28-.66).
Conclusions: Seasonal vaccination with RTS,S/AS01E induced a strong booster antibody response that was lower after the second than after the first booster dose. The diminished antibody response to the second booster dose was not associated with diminished efficacy.
Clinical Trials Registration: NCT03143218.
Competing Interests: Potential conflicts of interest. O. O.-A. is an employee of the GSK group of companies and has restricted shares in the GSK group of companies. A. D. reports a research grant from Grand Challenges Canada to test safety and efficacy of the PfSPZ vaccine for pregnant women and unborn children and a research contract with Oxford University to conduct a phase 3 randomized, controlled multicenter trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria outside of the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
(© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.)
References: J Infect Dis. 2016 Sep 1;214(5):762-71. (PMID: 27296848)
BMC Med. 2019 Aug 14;17(1):157. (PMID: 31409398)
BMC Med. 2014 Jul 10;12:117. (PMID: 25012228)
Malar J. 2017 May 2;16(1):182. (PMID: 28464937)
J Immunol. 2018 Aug 15;201(4):1315-1326. (PMID: 30006374)
PLoS One. 2014 Dec 15;9(12):e115126. (PMID: 25506706)
Trop Med Int Health. 2007 Jan;12(1):37-46. (PMID: 17207146)
PLoS One. 2009 Oct 02;4(10):e7302. (PMID: 19806184)
PLoS Med. 2014 Jul 29;11(7):e1001685. (PMID: 25072396)
Malar J. 2011 Aug 04;10:223. (PMID: 21816032)
J Infect Dis. 2014 Nov 15;210(10):1523-5. (PMID: 24823622)
Malar J. 2012 Nov 22;11:384. (PMID: 23173602)
Nat Commun. 2019 May 15;10(1):2174. (PMID: 31092823)
Vaccine. 2007 May 10;25(19):3816-26. (PMID: 17368878)
NPJ Vaccines. 2020 Jun 4;5:46. (PMID: 32550014)
Lancet Infect Dis. 2015 Dec;15(12):1450-8. (PMID: 26342424)
Front Immunol. 2017 Aug 23;8:1008. (PMID: 28878775)
Clin Exp Immunol. 2004 Feb;135(2):286-93. (PMID: 14738458)
J Infect Dis. 2020 Oct 13;222(10):1681-1691. (PMID: 32687161)
Sci Transl Med. 2020 Jul 22;12(553):. (PMID: 32718991)
Infect Immun. 2009 Oct;77(10):4502-9. (PMID: 19651872)
J Immunol. 2003 Dec 15;171(12):6961-7. (PMID: 14662904)
PLoS One. 2011;6(10):e25786. (PMID: 21998698)
Malar J. 2016 May 31;15:301. (PMID: 27245446)
PLoS One. 2012;7(12):e52870. (PMID: 23300801)
J Infect Dis. 1999 Nov;180(5):1656-64. (PMID: 10515829)
Front Big Data. 2021 Jun 15;4:672460. (PMID: 34212134)
BMJ Open. 2020 Sep 15;10(9):e035433. (PMID: 32933955)
N Engl J Med. 2021 Sep 9;385(11):1005-1017. (PMID: 34432975)
N Engl J Med. 2019 Jun 06;380(23):2197-2206. (PMID: 30699301)
NPJ Vaccines. 2021 Aug 30;6(1):110. (PMID: 34462438)
J Infect Dis. 2021 Oct 13;224(7):1128-1138. (PMID: 32236404)
Vaccine. 2020 Nov 3;38(47):7498-7507. (PMID: 33041104)
Lancet. 2001 Dec 8;358(9297):1927-34. (PMID: 11747915)
Elife. 2020 Apr 29;9:. (PMID: 32342859)
Lancet. 2015 Jul 4;386(9988):31-45. (PMID: 25913272)
Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2425-2430. (PMID: 28193898)
PLoS One. 2013 Apr 16;8(4):e61395. (PMID: 23613845)
معلومات مُعتمدة: 18269 PATH MVI; 220658/Z/20/Z Wellcome Trust and the Royal Society; MR/P006876/1 United Kingdom MRC_ Medical Research Council; United Kingdom WT_ Wellcome Trust; MR/R010161/1 United Kingdom MRC_ Medical Research Council
فهرسة مساهمة: Keywords: Burkina Faso; Mali; RTS; S/AS01E vaccine; anti-circumsporozoite antibody; seasonal vaccination
سلسلة جزيئية: ClinicalTrials.gov NCT03143218
المشرفين على المادة: 0 (Malaria Vaccines)
تواريخ الأحداث: Date Created: 20211211 Date Completed: 20220913 Latest Revision: 20230322
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9464075
DOI: 10.1093/cid/ciab1017
PMID: 34894221
قاعدة البيانات: MEDLINE
الوصف
تدمد:1537-6591
DOI:10.1093/cid/ciab1017